CD274 and non-small cell lung carcinoma: Moreover, the results of the phase I studies of M7824 indicated that this dual blockade therapeutic strategy was successful in clinical practice, especially for PD-L1-high NSCLC patients (objective response rate: 85.7%) [63, 64].